Disease · MONDO_0011399

alpha thalassemia spectrum

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. alpha thalassemia spectrum. Diseases, record MONDO_0011399. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011399

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: alpha thalassemia spectrum; Open Targets
Open Targets ID: MONDO_0011399; Open Targets
Other names: alpha thalassaemia, alpha thalassemia, thalassemia, alpha-, thalassemias, alpha-, α-thalassemia; Open Targets
Disease Ontology: DOID:1099; Disease Ontology
MeSH: D017085; MeSH
NCI Thesaurus: C34368; NCI Thesaurus
Orphanet: ORPHA:846; Orphanet
Highest stage of its drugs: Phase 3, for its one drug, from ClinicalTrials.gov; Open Targets

Drugs1

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here
MITAPIVAT	CHEMBL4299940	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3

Source Drugs and targets

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
PKLR	Pyruvate kinase PKLR	1	Pyruvate kinase isozymes R/L activator	Phase 3	https://conductscience.org/library/genes/5313

Source Drugs and targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04770779	A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)	Phase 3	258	2025-05-25	Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia	MITAPIVAT	Its record names the disease	ClinicalTrials.gov
NCT04770753	A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)	Phase 3	194	2025-01-24	Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia	MITAPIVAT	Its record names the disease	ClinicalTrials.gov
NCT03692052	A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia	Phase 2	20	2021-11-15	Thalassemia	MITAPIVAT	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Mitapivat vs Placebo: deaths from any cause	0 of 171	0 of 87	258	NCT04770779	Trial comparisons
Mitapivat vs Placebo: serious adverse events	19 of 172	13 of 85	257	NCT04770779	Trial comparisons
Mitapivat vs Placebo: deaths from any cause	0 of 130	0 of 64	194	NCT04770753	Trial comparisons
Mitapivat vs Placebo: serious adverse events	8 of 129	0 of 63	192	NCT04770753	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42721980	DERIVED	1	PubMed
40544857	DERIVED	1	PubMed
35964609	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0011399

GET https://conductscience.org/api/diseases/v1/MONDO_0011399/drugs

API reference For AI assistants